We claim:

1. A combination comprising pure 5-HT_6 receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist.

2. The combination as claimed in claim 1, wherein the pure 5-HT_6 receptor antagonist is selected from the group consisting of:
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
or a pharmaceutically acceptable salt thereof.

3. The combination as claimed in claim 1, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

4. The combination as claimed in claim 1, wherein the NMDA receptor antagonist is memantine.

5. The combination as claimed in claim 1 or claim 2, wherein the pure 5-HT_6 receptor antagonist is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

6. The combination as claimed in any one of the claim 1, 2 or 5, wherein the pharmaceutically acceptable salt of the pure 5-HT_6 receptor antagonist is,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride; and

1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride.

7. The combination as claimed in any one of the claim 1 to 4, wherein the pure 5-HT_6 receptor antagonist is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

8. The combination as claimed in claim 1 or claim 3, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.

9. The combination as claimed in any one of the claim 1, 3 or 8, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.

10. The combination as claimed in the claim 1 or claim 4, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

11. The combination as claimed in any one of the claim 1, 4 or 10, wherein the NMDA receptor antagonist is memantine hydrochloride.

12. A combination comprising 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, donepezil hydrochloride and memantine hydrochloride.

13. The combination as claimed in any one of the claim 1 to 12, for use in the treatment of cognitive disorders in a patient.

14. The use as claimed in claim 13, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia and frontotemporal dementia.

15. A method of treatment of cognitive disorders comprising administering to a patient in need thereof, a therapeutically effective amount of the combination as claimed in any one of the claim 1 to 12.

16. The method of treatment as claimed in 15, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia and frontotemporal dementia.

17. A compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof for use in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist for the treatment of Alzheimer's disease in a patient.

18. The compound for use as claimed in claim 17, as an adjunct treatment in a patient on stable treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist.

19. The compound for use as claimed in any one of the claim 17 or claim 18, wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

20. The compound for use as claimed in any one of the claim 17 or claim 18, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

21. A method of treating Alzheimer's disease in a patient on stable treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist comprising administering to said patient a therapeutically effective amount of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

22. The method of treating Alzheimer's disease as claimed in claim 21, wherein the acetylcholinesterase inhibitor is donepezil, rivastigmine and galantamine or the pharmaceutically acceptable salt thereof.

23. The method of treating Alzheimer's disease as claimed in claim 21, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

24. The method of treating Alzheimer's disease as claimed in claim 21, wherein the patient is administered 1 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

25. The method of treating Alzheimer's disease as claimed in claim 21, wherein the patient is administered 1 mg to 10 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

26. The method of treating Alzheimer's disease as claimed in claim 21, wherein the patient is administered 25 mg to 125 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

27. The method of treating Alzheimer's disease as claimed in claim 21, wherein the patient is administered 150 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

28. The method of treating Alzheimer's disease as claimed in claim 21, wherein the patient is administered 25 mg to 75 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

29. The method of treating Alzheimer's disease as claimed in claim 21, wherein the patient is administered 75 mg to 150 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

30. The method of treating Alzheimer's disease as claimed in claim 21, wherein the patient is administered 1 mg to 30 mg of donepezil or a pharmaceutically acceptable salt thereof per day.

31. The method of treating Alzheimer's disease as claimed in claim 21, wherein the patient is administered 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof per day.

32. A pharmaceutical composition comprising the combination as claimed in any one of the claim 1 to 12, and pharmaceutically acceptable excipients or combination thereof.

33. The pharmaceutical composition as claimed in claim 32, for use in the treatment of cognitive disorders selected from Alzheimer's disease, schizophrenia, Parkinson's diseases, lewy body dementia, vascular dementia and frontotemporal dementia.

34. The pharmaceutical composition as claimed in claim 32 or claim 33, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 1 mg to 300 mg.

35. The pharmaceutical composition as claimed in claim 32 or claim 33, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 35 mg to 200 mg.

36. The pharmaceutical composition as claimed in claim 32 or claim 33, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 200 mg to 300 mg.

37. The pharmaceutical composition as claimed in claim 30 or claim 31, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 75 mg or 150 mg.

38. The pharmaceutical composition as claimed in claim 32 or claim 33, wherein the donepezil or a pharmaceutically acceptable salt thereof is present in an amount of 2 mg to 30 mg.

39. The pharmaceutical composition as claimed in claim 32 or claim 33, wherein the memantine or a pharmaceutically acceptable salt thereof is present in an amount of 1 mg to 40 mg.

40. The method of treating Alzheimer's disease as claimed in claim 21, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is administered to the patient by oral, nasal, local, dermal or parenteral routes.

41. The method of treating Alzheimer's disease as claimed in claim 16, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is administered to the patient one to three times per day, one to three times per week or one to three times per month.